Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EASi-HF Reduced: Vicadrostat + Empagliflozin in HFrEF
jRCT2031250205Phase 3Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) comparing Vicadrostat + empagliflozin with Placebo + empagliflozin (2 arms). Primary endpoint: Time to first event of cardiovascular death, heart failure hospitalization, or urgent heart failure visit. Started Aug 2025; status: recruiting.
02
Drugs
vicadrostat
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on jRCT2031250205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250205.